MannKind Q2 2022 revenue $18.9M, net loss narrows to $29.0M; Tyvaso DPI approved

MANNKIND CORP

2022-Q2 EPS reported -$0.22 revenue$30,886,000

Commercial product net revenue $12.7M (Afrezza $10.6M, V-Go $2.1M), up 28% YoY; collaboration $5.9M.
Net loss $29.0M ($0.11/sh) vs $35.5M ($0.14/sh) in Q2 2021; narrowed due to prior-year debt extinguishment loss.
Tyvaso DPI (pulmonary hypertension) FDA approved May 2022; first manufacturing & royalty revenue from United Therapeutics recognized in Q2.
V-Go insulin patch acquisition May 31 generated $2.1M net revenue in June; gross profit $0.8M.
Afrezza gross margin improved to 68% from 56% on higher sales and lower COGS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.